Peptide Dosage Calculator: How to Calculate Reconstitution, Concentration & Dosing

Introduction to Peptide Dosage Calculations

Accurate dosage calculation is one of the most critical skills in peptide research. Whether you are reconstituting a lyophilized peptide for the first time or scaling protocols across multiple compounds, understanding the mathematics behind reconstitution, concentration, and volumetric dosing ensures reproducible results and minimizes waste of expensive research materials. Errors in peptide dosage calculations can compromise entire experimental protocols, leading to sub-therapeutic concentrations that fail to produce measurable effects or, conversely, excessive concentrations that confound dose-response data.

This comprehensive guide walks through every step of the peptide dosage calculation process, from basic unit conversions to advanced body-weight-based dosing formulas. We include worked examples for the most commonly studied research peptides, conversion tables, and practical tips to avoid the mistakes that frequently derail peptide research protocols. Whether you are working with BPC-157, semaglutide, CJC-1295, ipamorelin, or TB-500, the principles and formulas presented here apply universally across all peptide compounds.

Before diving into calculations, we strongly recommend reviewing our complete peptide reconstitution guide for the physical handling procedures and our peptide storage and temperature guide to ensure your reconstituted peptides maintain stability throughout your research protocol.

Essential Unit Conversions for Peptide Research

The foundation of all peptide dosage calculations rests on understanding the relationships between mass and volume units. Peptides are typically supplied as lyophilized powders measured in milligrams (mg), while dosing protocols specify amounts in micrograms (mcg or µg), and injection volumes are measured in milliliters (mL) or International Units (IU) on insulin syringes. Mastering these conversions eliminates the most common source of dosing errors.

Mass Conversions

Conversion	Formula	Example
Milligrams to Micrograms	mg × 1,000 = mcg	5 mg = 5,000 mcg
Micrograms to Milligrams	mcg ÷ 1,000 = mg	250 mcg = 0.25 mg
Grams to Milligrams	g × 1,000 = mg	0.01 g = 10 mg
Milligrams to Grams	mg ÷ 1,000 = g	5 mg = 0.005 g
Micrograms to Nanograms	mcg × 1,000 = ng	100 mcg = 100,000 ng

Volume Conversions

Conversion	Formula	Example
Milliliters to Units (insulin syringe)	mL × 100 = IU	0.5 mL = 50 IU
Units to Milliliters	IU ÷ 100 = mL	10 IU = 0.1 mL
Milliliters to Cubic Centimeters	1 mL = 1 cc	2 mL = 2 cc

Critical note on insulin syringes: Standard U-100 insulin syringes are calibrated so that 100 units equals 1 mL. This is the standard used throughout peptide research. U-40 or U-50 syringes exist but are rarely used in peptide protocols, and using them with U-100 calculations will result in significant dosing errors. Always verify your syringe calibration before performing calculations.

The Master Reconstitution Formula

Reconstitution is the process of dissolving lyophilized (freeze-dried) peptide powder with a suitable diluent, most commonly bacteriostatic water (BAC water). The amount of diluent you add directly determines the concentration of the resulting solution, which in turn determines how much volume you need to draw for each dose.

The Core Formula

The fundamental relationship governing peptide reconstitution is:

Concentration = Total Peptide Amount ÷ Total Diluent Volume

Or expressed with units:

Concentration (mcg/mL) = Peptide Amount (mcg) ÷ Diluent Volume (mL)

This can be rearranged to solve for any variable:

• To find required diluent volume: Volume (mL) = Peptide Amount (mcg) ÷ Desired Concentration (mcg/mL)
• To find dose volume: Dose Volume (mL) = Desired Dose (mcg) ÷ Concentration (mcg/mL)
• To find dose in a given volume: Dose (mcg) = Concentration (mcg/mL) × Volume Drawn (mL)

Step-by-Step Reconstitution Calculation

Let us walk through a complete example using a 5 mg vial of BPC-157 reconstituted with 2 mL of bacteriostatic water:

Step 1: Convert peptide amount to micrograms

5 mg × 1,000 = 5,000 mcg

Step 2: Calculate concentration

5,000 mcg ÷ 2 mL = 2,500 mcg/mL

Step 3: Determine dose volume

If your protocol calls for 250 mcg per dose:

250 mcg ÷ 2,500 mcg/mL = 0.1 mL = 10 IU on an insulin syringe

Step 4: Calculate total doses per vial

5,000 mcg ÷ 250 mcg per dose = 20 doses

Or by volume: 2 mL ÷ 0.1 mL per dose = 20 doses

This confirms the vial will provide 20 doses at 250 mcg each when reconstituted with 2 mL of diluent. For detailed reconstitution handling procedures, including proper injection technique for adding diluent, see our peptide reconstitution guide.

Choosing Your Reconstitution Volume

The amount of bacteriostatic water you add to a peptide vial is not arbitrary. It determines the concentration, which affects both the precision of dosing and the practicality of administration. There are several important factors to consider when selecting your reconstitution volume.

Common Reconstitution Volumes and Their Applications

Peptide Amount	BAC Water	Concentration	Best For
5 mg	1 mL	5,000 mcg/mL	High-dose protocols, fewer injections
5 mg	2 mL	2,500 mcg/mL	Standard dosing, good precision
5 mg	2.5 mL	2,000 mcg/mL	Easy math, moderate precision
5 mg	5 mL	1,000 mcg/mL	Low-dose protocols, maximum precision
10 mg	2 mL	5,000 mcg/mL	High-dose protocols
10 mg	3 mL	3,333 mcg/mL	Moderate dosing
10 mg	5 mL	2,000 mcg/mL	Standard dosing with easy math
2 mg	1 mL	2,000 mcg/mL	Standard for 2 mg vials
2 mg	2 mL	1,000 mcg/mL	Easy calculations for low-dose protocols

Factors Influencing Reconstitution Volume Choice

Dose size: If your protocol requires very small doses (e.g., 50–100 mcg), use more diluent to create a lower concentration. This allows you to draw a larger, more measurable volume, improving accuracy. Drawing 0.05 mL (5 IU) is far less precise than drawing 0.25 mL (25 IU).

Syringe graduation: Standard 1 mL (100 IU) insulin syringes typically have markings every 2 IU (0.02 mL). Smaller 0.5 mL (50 IU) syringes often have markings every 1 IU (0.01 mL). Choose a reconstitution volume that results in dose volumes aligning with your syringe graduations.

Vial usage timeline: More diluent means a more dilute solution, which means drawing more volume per dose, which means the vial empties faster relative to its number of doses. Consider how quickly you will use the vial, as reconstituted peptides have a limited stability window even when properly stored. Refer to our storage guide for stability timelines.

Injection volume comfort: For subcutaneous administration in research models, volumes between 0.1 mL and 0.5 mL are generally optimal. Volumes below 0.05 mL are difficult to measure accurately, while volumes above 1 mL may cause discomfort at the injection site.

Insulin Syringe Units Explained

Insulin syringes are the standard tool for measuring and administering peptide solutions in research settings. Understanding how they work is essential for accurate dosing.

U-100 Insulin Syringe Breakdown

The U-100 designation means the syringe is calibrated for insulin at a concentration of 100 units per milliliter. For peptide research, we ignore the “insulin units” designation and simply use the syringe as a precise volume-measuring device:

Syringe Reading (IU)	Volume (mL)	Volume (µL)
1 IU	0.01 mL	10 µL
5 IU	0.05 mL	50 µL
10 IU	0.10 mL	100 µL
15 IU	0.15 mL	150 µL
20 IU	0.20 mL	200 µL
25 IU	0.25 mL	250 µL
30 IU	0.30 mL	300 µL
40 IU	0.40 mL	400 µL
50 IU	0.50 mL	500 µL
75 IU	0.75 mL	750 µL
100 IU	1.00 mL	1,000 µL

Choosing the Right Syringe Size

Insulin syringes come in three main sizes, each suited to different dose volumes:

• 0.3 mL (30 IU) syringes: Best for very small doses. Graduations are typically every 0.5 IU (0.005 mL), providing the highest precision. Ideal for doses under 0.2 mL.
• 0.5 mL (50 IU) syringes: Good all-around choice. Graduations every 1 IU (0.01 mL). Suitable for doses between 0.1–0.5 mL.
• 1.0 mL (100 IU) syringes: Largest standard size. Graduations every 2 IU (0.02 mL). Best for doses between 0.3–1.0 mL.

Precision tip: Always use the smallest syringe that can accommodate your dose volume. A 10 IU dose measured on a 30 IU syringe is far more accurate than the same dose on a 100 IU syringe, because the graduation marks are spaced further apart and easier to read precisely.

Detailed Calculation Examples for Popular Research Peptides

The following worked examples cover the most commonly studied research peptides. Each example walks through the complete calculation process from reconstitution to final dose volume. These examples represent commonly cited research protocol concentrations found in the published literature and are provided for educational purposes.

Example 1: BPC-157 (Body Protection Compound-157)

BPC-157 is one of the most widely studied peptides in regenerative research, with extensive literature on its tissue-protective and healing properties. For a thorough review of the science, see our BPC-157 research guide.

Vial: 5 mg BPC-157

Diluent: 2 mL bacteriostatic water

Protocol dose: 250 mcg (a commonly studied dose in the literature, referenced in Sikiric et al., 2010)

Calculation:

1. 5 mg × 1,000 = 5,000 mcg total
2. 5,000 mcg ÷ 2 mL = 2,500 mcg/mL
3. 250 mcg ÷ 2,500 mcg/mL = 0.10 mL = 10 IU
4. Total doses: 5,000 ÷ 250 = 20 doses per vial

BPC-157 is also available in oral tablet form, which eliminates the need for reconstitution calculations entirely. Additionally, the Wolverine Blend combines BPC-157 with TB-500 for researchers studying synergistic tissue repair mechanisms. For protocols combining multiple peptides, consult our peptide stacking guide.

Example 2: Semaglutide

Semaglutide is a GLP-1 receptor agonist studied extensively for metabolic research. Its dosing follows a well-characterized titration schedule, which makes accurate calculation especially important. Review the full pharmacology in our semaglutide research guide.

Vial: 5 mg semaglutide

Diluent: 2.5 mL bacteriostatic water

Concentration: 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL

Typical Research Titration Schedule:

Week	Dose	Volume to Draw	Syringe (IU)
1–4	250 mcg	0.125 mL	12.5 IU
5–8	500 mcg	0.25 mL	25 IU
9–12	1,000 mcg	0.50 mL	50 IU
13–16	1,700 mcg	0.85 mL	85 IU
17+	2,400 mcg	1.20 mL	120 IU*

*Note: The 2,400 mcg dose exceeds 1 mL, requiring either a larger syringe or splitting into two injections. Many researchers adjust the reconstitution volume to accommodate higher doses within a single syringe draw. For instance, reconstituting with 1 mL instead of 2.5 mL yields 5,000 mcg/mL, making the 2,400 mcg dose only 0.48 mL (48 IU).

Semaglutide is typically administered once weekly in research protocols, as its half-life of approximately 7 days (demonstrated in Kapitza et al., 2017) allows for sustained receptor activation. For fat loss research applications, see our peptides for fat loss guide which compares semaglutide with other metabolic peptides including tirzepatide and retatrutide.

Example 3: CJC-1295 (no DAC)

CJC-1295 without DAC (also called Modified GRF 1-29) is a growth hormone releasing hormone analog frequently studied in combination with ipamorelin. For comprehensive background, see our growth hormone secretagogues guide.

Vial: 5 mg CJC-1295 (no DAC)

Diluent: 2.5 mL bacteriostatic water

Protocol dose: 100 mcg (commonly studied dose, per Ionescu & Bhatt, 2006)

Calculation:

1. 5 mg × 1,000 = 5,000 mcg
2. 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL
3. 100 mcg ÷ 2,000 mcg/mL = 0.05 mL = 5 IU
4. Total doses: 5,000 ÷ 100 = 50 doses per vial

CJC-1295 is most commonly studied alongside ipamorelin in growth hormone pulse protocols. Using the same reconstitution approach for both peptides simplifies multi-peptide protocols significantly.

Example 4: Ipamorelin

Ipamorelin is a selective growth hormone secretagogue peptide (GHSP) that stimulates GH release with high specificity. It is often paired with CJC-1295 for synergistic GH pulse amplification, a protocol discussed in detail in our peptide stacking guide.

Vial: 5 mg ipamorelin

Diluent: 2.5 mL bacteriostatic water

Protocol dose: 200 mcg (commonly studied dose based on research by Raun et al., 1998)

Calculation:

1. 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL
2. 200 mcg ÷ 2,000 mcg/mL = 0.10 mL = 10 IU
3. Total doses: 5,000 ÷ 200 = 25 doses per vial

Combined CJC-1295 + Ipamorelin protocol: When studying these two peptides together, you would draw 5 IU of CJC-1295 (100 mcg) and 10 IU of ipamorelin (200 mcg) separately, administered at the same time. This combined protocol is one of the most frequently studied growth hormone secretagogue stacks in the literature.

Example 5: TB-500 (Thymosin Beta-4)

TB-500 is studied for its roles in tissue repair, cell migration, and anti-inflammatory signaling. For full background, see our TB-500 research guide.

Vial: 5 mg TB-500

Diluent: 1 mL bacteriostatic water

Protocol dose: 2,500 mcg (2.5 mg) — a loading-phase dose commonly studied, per Crockford, 2007

Calculation:

1. 5,000 mcg ÷ 1 mL = 5,000 mcg/mL
2. 2,500 mcg ÷ 5,000 mcg/mL = 0.50 mL = 50 IU
3. Total doses: 5,000 ÷ 2,500 = 2 doses per vial

TB-500 is frequently studied in combination with BPC-157 for synergistic tissue repair effects. The Wolverine Blend pre-combines these two peptides for convenience. Researchers interested in joint and connective tissue applications should also review our peptides for joint health article.

Example 6: Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has generated significant research interest for its metabolic effects. Like semaglutide, it follows a titration schedule in research protocols.

Vial: 5 mg tirzepatide

Diluent: 1 mL bacteriostatic water

Concentration: 5,000 mcg/mL

Research Titration Schedule:

Phase	Dose	Volume	Syringe (IU)
Weeks 1–4	2,500 mcg (2.5 mg)	0.50 mL	50 IU
Weeks 5–8	5,000 mcg (5.0 mg)	1.00 mL	100 IU
Weeks 9–12	7,500 mcg (7.5 mg)	1.50 mL*	150 IU*
Weeks 13+	10,000 mcg (10.0 mg)	2.00 mL*	200 IU*

*Higher doses require reconstituting with more bacteriostatic water for higher concentration, or using multiple vials. For instance, reconstituting 10 mg with 1 mL yields 10,000 mcg/mL, making the 10 mg dose a simple 1 mL draw. The SURPASS clinical trial program demonstrated tirzepatide’s dose-dependent metabolic effects (Frias et al., 2021).

Example 7: AOD 9604

AOD 9604 is a modified fragment of human growth hormone (hGH fragment 177-191) studied for its lipolytic properties. For complete research background, see our AOD 9604 research guide.

Vial: 5 mg AOD 9604

Diluent: 2.5 mL bacteriostatic water

Protocol dose: 300 mcg (based on clinical research dosing, Heffernan et al., 2001)

Calculation:

1. 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL
2. 300 mcg ÷ 2,000 mcg/mL = 0.15 mL = 15 IU
3. Total doses: 5,000 ÷ 300 = 16.7 doses per vial (approximately 16 full doses)

Body Weight-Based Dosing Calculations

Many peptide research protocols specify doses relative to body weight, typically expressed as micrograms per kilogram (mcg/kg). This approach normalizes exposure across research subjects of different sizes, improving dose-response consistency. Animal studies frequently use body weight-based dosing, and translational research requires understanding these calculations to interpret published data accurately.

The Body Weight Dosing Formula

Total Dose (mcg) = Body Weight (kg) × Dose Rate (mcg/kg)

If body weight is known in pounds, first convert:

Weight (kg) = Weight (lbs) ÷ 2.205

Body Weight Dosing Example Table

For a protocol specifying 10 mcg/kg of BPC-157 (a common preclinical dose referenced in Sikiric et al., 2003):

Body Weight (kg)	Body Weight (lbs)	Dose at 10 mcg/kg	Volume* (mL)	Syringe (IU)
55	121	550 mcg	0.22 mL	22 IU
60	132	600 mcg	0.24 mL	24 IU
70	154	700 mcg	0.28 mL	28 IU
80	176	800 mcg	0.32 mL	32 IU
90	198	900 mcg	0.36 mL	36 IU
100	220	1,000 mcg	0.40 mL	40 IU
110	243	1,100 mcg	0.44 mL	44 IU

*Assuming concentration of 2,500 mcg/mL (5 mg in 2 mL)

Allometric Scaling: Converting Animal Doses to Human Equivalent Doses

When interpreting preclinical peptide research, understanding how to convert animal doses to human equivalent doses (HED) is valuable for protocol design. The FDA-recommended allometric scaling approach accounts for differences in body surface area (Reagan-Shaw et al., 2008):

HED (mg/kg) = Animal Dose (mg/kg) × (Animal Km ÷ Human Km)

Species	Km Factor	Conversion to HED
Mouse	3	Divide mouse dose by 12.3
Rat	6	Divide rat dose by 6.2
Rabbit	12	Divide rabbit dose by 3.1
Dog	20	Divide dog dose by 1.8
Human	37	Reference

For example, if a mouse study uses BPC-157 at 10 mcg/kg, the human equivalent dose would be approximately 10 ÷ 12.3 = 0.81 mcg/kg. For a 75 kg subject, that translates to approximately 61 mcg. This explains why human research protocols often use doses that appear much lower per-kg than animal studies.

Dose Titration Protocols

Titration—gradually increasing the dose over time—is a standard practice in peptide research that helps identify optimal dosing ranges while minimizing adverse effects. This is particularly important for peptides with dose-dependent side effect profiles.

General Titration Principles

• Start low: Begin at the lowest effective dose suggested by the literature
• Increase gradually: Step up by 25–50% per interval, not doubling or tripling
• Maintain intervals: Allow enough time at each dose level for steady-state to be approached (typically 3–5 half-lives)
• Document response: Record biomarkers and observations at each dose level before escalating
• Respect ceilings: Most peptides have a dose ceiling beyond which additional compound produces diminishing returns with increasing side effects

For an in-depth discussion of cycling and periodization strategies, see our peptide cycling guide.

GLP-1 Agonist Titration (Semaglutide/Tirzepatide/Retatrutide)

GLP-1 agonists require careful titration to manage gastrointestinal tolerability. The standard approach documented in clinical trials involves 4-week dose escalation steps:

Peptide	Starting Dose	Step 2	Step 3	Step 4	Maintenance
Semaglutide	250 mcg	500 mcg	1,000 mcg	1,700 mcg	2,400 mcg
Tirzepatide	2,500 mcg	5,000 mcg	7,500 mcg	10,000 mcg	15,000 mcg
Retatrutide	1,000 mcg	2,000 mcg	4,000 mcg	8,000 mcg	12,000 mcg

Retatrutide, as a triple agonist (GLP-1/GIP/glucagon), has a unique titration profile discussed in our retatrutide research guide. Its glucagon receptor component introduces additional metabolic effects that warrant careful dose escalation.

Quick-Reference Dosing Tables

The following comprehensive tables provide at-a-glance dosing information for the most commonly studied research peptides. All calculations assume standard reconstitution volumes with bacteriostatic water.

5 mg Vial Quick Reference (Reconstituted with 2 mL BAC Water = 2,500 mcg/mL)

Desired Dose (mcg)	Volume (mL)	Syringe (IU)	Doses Per Vial
100	0.04	4 IU	50
150	0.06	6 IU	33
200	0.08	8 IU	25
250	0.10	10 IU	20
300	0.12	12 IU	16
400	0.16	16 IU	12
500	0.20	20 IU	10
750	0.30	30 IU	6
1,000	0.40	40 IU	5
1,500	0.60	60 IU	3
2,000	0.80	80 IU	2
2,500	1.00	100 IU	2

10 mg Vial Quick Reference (Reconstituted with 2 mL BAC Water = 5,000 mcg/mL)

Desired Dose (mcg)	Volume (mL)	Syringe (IU)	Doses Per Vial
100	0.02	2 IU	100
200	0.04	4 IU	50
250	0.05	5 IU	40
500	0.10	10 IU	20
1,000	0.20	20 IU	10
1,500	0.30	30 IU	6
2,000	0.40	40 IU	5
2,500	0.50	50 IU	4
5,000	1.00	100 IU	2

Peptide-Specific Dosing Summary

Peptide	Common Research Dose	Frequency	Reconstitution	Draw Volume
BPC-157	250–500 mcg	1–2x daily	5 mg + 2 mL	10–20 IU
TB-500	2,000–2,500 mcg	2x weekly (loading)	5 mg + 1 mL	40–50 IU
Semaglutide	250–2,400 mcg	1x weekly	5 mg + 2.5 mL	12.5–120 IU
Tirzepatide	2,500–15,000 mcg	1x weekly	Varies	Varies
Retatrutide	1,000–12,000 mcg	1x weekly	Varies	Varies
CJC-1295	100 mcg	1–3x daily	5 mg + 2.5 mL	5 IU
Ipamorelin	100–300 mcg	1–3x daily	5 mg + 2.5 mL	5–15 IU
AOD 9604	250–300 mcg	1x daily	5 mg + 2.5 mL	12.5–15 IU
Tesamorelin	1,000–2,000 mcg	1x daily	2 mg + 2 mL	100 IU
GHK-Cu	200–500 mcg	1x daily	5 mg + 2 mL	8–20 IU
Semax	200–600 mcg	1–2x daily	10 mg + 5 mL	10–30 IU
KPV	200–500 mcg	1x daily	10 mg + 5 mL	10–25 IU
MOTS-C	5,000–10,000 mcg	3–5x weekly	10 mg + 1 mL	50–100 IU
Melanotan II	250–500 mcg	Daily (loading)	10 mg + 2 mL	5–10 IU

Advanced Calculation Scenarios

Scenario 1: Adjusting Concentration Mid-Protocol

Sometimes you may need to adjust your reconstitution strategy mid-protocol. For instance, if you begin a semaglutide titration with a low concentration suitable for the starting dose but need a higher concentration for the maintenance dose:

Initial vial: 5 mg semaglutide in 5 mL BAC water = 1,000 mcg/mL

At 250 mcg/dose, this requires 0.25 mL (25 IU)—very precise and easy to measure.

Problem: At the maintenance dose of 2,400 mcg, you would need 2.4 mL per dose—the vial would only provide about 2 doses, and you would need a 3 mL syringe.

Solution: For the next vial, reconstitute with just 1 mL to get 5,000 mcg/mL. Now the 2,400 mcg dose is only 0.48 mL (48 IU)—easily measurable with a standard 1 mL insulin syringe.

Scenario 2: Multi-Peptide Protocol Calculation

Researchers studying the combination of BPC-157 + TB-500 for tissue repair (also available as the Wolverine Blend) need to calculate both peptides independently:

BPC-157: 5 mg vial + 2 mL BAC water = 2,500 mcg/mL. At 250 mcg/dose = 0.10 mL (10 IU). Administered 2x daily.

TB-500: 5 mg vial + 1 mL BAC water = 5,000 mcg/mL. At 2,500 mcg/dose = 0.50 mL (50 IU). Administered 2x weekly.

Weekly consumption:

• BPC-157: 250 mcg × 14 doses = 3,500 mcg/week (uses 0.7 of a 5 mg vial)
• TB-500: 2,500 mcg × 2 doses = 5,000 mcg/week (uses exactly one 5 mg vial)

This consumption rate helps with inventory planning for multi-week research protocols.

Scenario 3: Dead Volume Compensation

Every syringe has a small amount of “dead volume”—liquid that remains in the needle hub and cannot be expelled. For standard insulin syringes, this is approximately 0.005–0.01 mL (0.5–1 IU). Over the course of a vial, dead volume can add up:

Example: A 5 mg BPC-157 vial providing 20 doses of 250 mcg at 10 IU each. With 0.5 IU dead volume per injection, you lose approximately 0.5 × 20 = 10 IU = 0.10 mL of solution over the vial’s lifetime. At 2,500 mcg/mL, that’s 250 mcg of peptide lost—the equivalent of one full dose.

To compensate, some researchers add slightly more diluent during reconstitution or accept that the last dose from each vial may be slightly under-filled. Using low-dead-volume (LDV) syringes can reduce this waste to negligible levels.

Common Calculation Mistakes and How to Avoid Them

Even experienced researchers occasionally make calculation errors that can compromise their protocols. Here are the most frequent mistakes and their solutions:

Mistake 1: Confusing mg and mcg

This is by far the most dangerous error. A vial labeled “5 mg” contains 5,000 mcg. Confusing these units can result in a 1,000-fold dosing error.

Prevention: Always convert your vial amount to the same unit as your target dose before calculating. If your protocol specifies mcg, convert the vial label to mcg first. Write out the full calculation and double-check the units at each step.

Mistake 2: Using the Wrong Syringe Calibration

U-40 insulin syringes are calibrated differently from U-100 syringes. Drawing “10 units” on a U-40 syringe actually draws 0.25 mL (not 0.10 mL). This causes a 2.5x overdose.

Prevention: Always verify your syringe type. U-100 syringes are standard for peptide research. If in doubt, check the label: it will clearly state U-100 or U-40.

Mistake 3: Not Accounting for Peptide Purity

Peptide purity affects the actual amount of active compound. A vial labeled “5 mg” with 98% purity contains 4.9 mg of active peptide. While this difference is minor, it compounds across multiple calculations. Always check the Certificate of Analysis (CoA)—our guide on how to read a peptide CoA explains what to look for.

Mistake 4: Forgetting Reconstitution Volume in Concentration

Some researchers calculate based on the vial amount without accounting for the diluent volume, or they add diluent but forget to recalculate concentration when they add a different volume than planned.

Prevention: Measure your bacteriostatic water carefully before adding it. If you accidentally add 2.3 mL instead of 2.0 mL, recalculate: 5,000 mcg ÷ 2.3 mL = 2,174 mcg/mL (not 2,500). Document the actual volume used.

Mistake 5: Assuming All Peptide Vials Are the Same Size

Different peptides come in different vial amounts. BPC-157 is commonly supplied in 5 mg vials, while Semax comes in 10 mg vials and KPV also in 10 mg vials. Always verify the vial amount before reconstituting.

Mistake 6: Drawing Air Bubbles

Air bubbles in the syringe displace liquid volume, causing underdosing. A single large air bubble can reduce the actual drawn volume by 5–20%.

Prevention: After drawing your dose, hold the syringe needle-up and tap it gently to move air bubbles to the top. Push the plunger up carefully to expel the air, then adjust the drawn volume if needed.

Mistake 7: Not Accounting for Peptide Powder Volume

Lyophilized peptide powder occupies negligible volume (typically less than 0.01 mL for a 5 mg vial), so it does not significantly affect concentration calculations. However, for very large peptide amounts or when using minimal diluent volumes, this should be verified. In practice, for vials up to 10 mg with standard reconstitution volumes (1–5 mL), powder volume can be safely ignored.

Creating a Personalized Dosing Chart

For researchers running multi-week protocols with multiple peptides, creating a personalized dosing chart prevents daily calculation errors and streamlines the research process. Here is a template approach:

Step 1: List All Peptides in Your Protocol

For each peptide, record:

• Vial size (mg)
• Reconstitution volume (mL BAC water)
• Resulting concentration (mcg/mL)
• Target dose (mcg)
• Dose volume (mL and IU)
• Administration frequency

Step 2: Calculate Weekly and Monthly Consumption

Multiply the dose by the frequency to determine how quickly vials are consumed:

Example protocol: Growth Hormone Secretagogue Stack

Peptide	Dose	Frequency	Weekly Use	Vial Size	Vials/Month
CJC-1295	100 mcg	5x/week	500 mcg	5 mg	0.43
Ipamorelin	200 mcg	5x/week	1,000 mcg	5 mg	0.87
Total	—	—	—	—	~1.3 vials total

For a 12-week (3-month) protocol, you would need approximately 2 vials of CJC-1295 and 3 vials of ipamorelin.

Step 3: Build Your Daily Schedule

Map out exactly when each peptide is administered and the exact syringe draw for each. Print this chart and keep it at your research station. This eliminates the need to recalculate each day and reduces the risk of errors during routine administration.

Special Considerations for Specific Peptide Categories

GLP-1 Receptor Agonists

Semaglutide, tirzepatide, and retatrutide are all administered weekly and follow titration schedules. Key considerations include:

• Always start at the lowest dose in the titration schedule
• Never skip dose tiers—gradual escalation is critical for tolerability
• Weekly dosing means reconstituted vials need to remain stable for extended periods; proper storage is essential
• These peptides have relatively long half-lives, meaning missed doses have less impact than with short-acting peptides

For a comprehensive comparison of these compounds, see our fat loss peptides research guide.

Growth Hormone Secretagogues

CJC-1295, ipamorelin, and tesamorelin are typically administered daily or multiple times daily. Important dosing considerations include:

• Timing relative to meals matters—most protocols specify fasted administration
• Multiple daily doses increase the number of syringe draws per vial, making dead volume a larger concern
• These peptides are often stacked together, requiring separate reconstitution and separate syringe draws
• Pulse protocols (e.g., CJC-1295 + ipamorelin administered simultaneously) aim to amplify GH pulsatility

Our growth hormone secretagogues guide covers the pharmacology behind these dosing strategies in detail.

Tissue Repair Peptides

BPC-157 and TB-500 are the primary tissue repair peptides. Dosing considerations include:

• BPC-157 is typically studied at lower absolute doses (250–500 mcg) but higher frequency (1–2x daily)
• TB-500 uses higher absolute doses (2–2.5 mg) but lower frequency (2x weekly loading, then 1x weekly maintenance)
• Local (near the injury site) versus systemic administration may affect dosing choices
• The Wolverine Blend simplifies combined protocols by pre-mixing both peptides

Explore both peptides’ mechanisms in our BPC-157 guide and TB-500 guide.

Neuroprotective Peptides

Semax is typically administered intranasally rather than by subcutaneous injection. Intranasal dosing follows different calculation principles since spray devices deliver a fixed volume per actuation. Standard nasal spray devices deliver approximately 0.1 mL per spray. With a 10 mg vial reconstituted in 5 mL (2,000 mcg/mL), each spray delivers approximately 200 mcg.

Reconstitution Best Practices Summary

Before performing any of the calculations described in this guide, ensure your reconstitution technique is correct. Errors in the physical reconstitution process will render even perfect calculations meaningless:

1. Use the correct diluent: Bacteriostatic water (0.9% benzyl alcohol) is the standard for multi-use reconstitution. Sterile water can be used for single-use situations but lacks preservative for multi-dose vials.
2. Inject along the vial wall: Direct the stream of bacteriostatic water down the inside wall of the vial, not directly onto the peptide cake. This prevents damage to the peptide structure and aids dissolution.
3. Do not shake: Gentle swirling is acceptable; vigorous shaking can denature peptides. Most peptides dissolve within 1–2 minutes with gentle swirling.
4. Verify clarity: A properly reconstituted peptide solution should be clear and colorless. Cloudy solutions or visible particles may indicate degradation, contamination, or incomplete dissolution.
5. Store correctly: Reconstituted peptides should be refrigerated at 2–8°C (36–46°F). Most reconstituted peptides maintain stability for 4–6 weeks when properly stored. See our storage temperature guide for compound-specific timelines.
6. Document everything: Record the date of reconstitution, diluent volume used, and calculated concentration on the vial label. This prevents confusion in multi-vial, multi-peptide protocols.

Verification Checklist

Before every dose, walk through this mental checklist to verify your calculation:

1. Vial amount confirmed? Check the label—is it 2 mg, 5 mg, or 10 mg?
2. Reconstitution volume recorded? How much BAC water did you add?
3. Concentration calculated correctly? Total mcg ÷ total mL = mcg/mL
4. Target dose in correct units? Is your protocol specifying mcg or mg?
5. Draw volume makes sense? Dose ÷ concentration = volume. Does the result seem reasonable?
6. Syringe reading correct? Volume in mL × 100 = IU. Does your syringe reading match?
7. No air bubbles? Check syringe for air before administration.
8. Correct peptide? If running multiple peptides, verify you are drawing from the right vial.

Frequently Asked Questions

Can I mix different peptides in the same syringe?

While physically possible, mixing peptides in the same syringe is generally not recommended unless they are specifically formulated together (like the Wolverine Blend). Different peptides may interact chemically, potentially causing degradation or aggregation. Use separate syringes for each peptide and administer at different sites.

What if I added too much or too little bacteriostatic water?

If you added too much, you can still use the vial—just recalculate the concentration with the actual volume used. If you added too little, you can add more (gently swirl to mix), then calculate based on the total volume. The key is knowing the exact total volume of diluent added so you can calculate the true concentration.

How do I handle peptides that come as pre-mixed solutions?

Some peptides, like Oral BPC-157 tablets, come in pre-dosed forms that eliminate the need for reconstitution calculations entirely. For liquid formulations, the concentration is specified on the label—simply use the dose-volume formula with the stated concentration.

Does the gauge of the needle affect the dosing volume?

Needle gauge affects the internal bore diameter of the needle, which creates a small dead volume within the needle itself. The difference between common gauges (27G, 29G, 30G, 31G) is negligible for most practical purposes. However, when measuring very small volumes (under 5 IU / 0.05 mL), even small dead volume differences can be proportionally significant. Low-dead-volume syringes are recommended for micro-dosing protocols.

What if my peptide does not fully dissolve?

If the peptide cake does not fully dissolve after 5 minutes of gentle swirling, the vial may be exposed to degradation or contamination. Do not attempt to force dissolution by shaking or heating. A small amount of undissolved material at the bottom of the vial is sometimes normal and may represent excipients (inactive ingredients) rather than peptide. However, significantly undissolved powder or cloudy solutions should raise quality concerns—check the CoA and storage history. Our CoA interpretation guide can help assess quality.

Peptide Half-Life and Dosing Frequency

Understanding a peptide’s half-life is essential for designing effective dosing schedules. The half-life determines how long a peptide remains active in the body at pharmacologically relevant concentrations, which directly influences how often it must be administered to maintain consistent biological effects. Dosing too infrequently allows peptide levels to drop below the effective threshold, while dosing too frequently may lead to accumulation effects or unnecessary waste of research material.

Half-Life Reference Table for Common Research Peptides

Peptide	Approximate Half-Life	Typical Dosing Frequency	Time to Steady State
BPC-157	4–6 hours	1–2x daily	1–2 days
TB-500	~12 hours (effective duration longer)	2x weekly	1–2 weeks
Semaglutide	~7 days (168 hours)	1x weekly	4–5 weeks
Tirzepatide	~5 days (120 hours)	1x weekly	4–5 weeks
Retatrutide	~6 days (144 hours)	1x weekly	4–5 weeks
CJC-1295 (no DAC)	~30 minutes	1–3x daily	1 day
Ipamorelin	~2 hours	1–3x daily	1 day
AOD 9604	~30–60 minutes	1x daily	1 day
GHK-Cu	~1–2 hours (topical: longer local duration)	1x daily	1–2 days
MOTS-C	~8–12 hours (estimated)	3–5x weekly	1–2 weeks
Melanotan II	~1 hour (effects persist much longer)	Daily (loading), then 2x weekly	Variable
Semax	~30 seconds (intranasal bioavailability extends effective duration)	1–3x daily	1 day

How Half-Life Affects Dosing Calculations

The relationship between half-life and dosing frequency has direct implications for your calculations in two important ways:

Vial consumption rate: Peptides with short half-lives that require multiple daily doses will consume vials much faster than weekly-dosed peptides. For example, BPC-157 at 250 mcg twice daily consumes 3,500 mcg per week from a 5,000 mcg vial, meaning a single vial lasts approximately 10 days. In contrast, semaglutide at 500 mcg once weekly consumes only 500 mcg per week, meaning a 5 mg vial could theoretically last 10 weeks at that dose level.

Reconstituted stability window: Once reconstituted with bacteriostatic water, most peptides maintain stability for 4–6 weeks when properly refrigerated. For peptides dosed frequently (daily or twice daily), the vial is typically consumed well within this stability window. For peptides dosed weekly, however, a single reconstituted vial may need to remain stable for many weeks. This is an important consideration when choosing reconstitution volumes—reconstituting with too much diluent may result in a solution that expires before all doses are used. For detailed stability data, see our peptide storage temperature guide.

Steady-state accumulation: For peptides with long half-lives (such as semaglutide at 7 days), drug levels accumulate over multiple doses before reaching steady state. At steady state, the amount entering the system per dose equals the amount eliminated between doses. This accumulation means that the effective peak concentration at steady state is higher than after the first dose, which is one reason why GLP-1 agonists use titration schedules—starting low allows the body to adapt as levels gradually build to the steady-state concentration at each dose tier.

Reconstitution Volume Optimization by Protocol Duration

One often-overlooked aspect of peptide dosage calculation is optimizing your reconstitution volume based on how long your protocol will last and how quickly you will consume the vial. This optimization balances three competing priorities: dosing precision, solution stability, and practical convenience.

Short Protocols (1–2 Weeks)

For short-duration research protocols, reconstitution volume is less critical because the vial will be consumed quickly. Prioritize dosing precision by using enough diluent to make the dose volume easy to measure accurately. For example, if studying BPC-157 at 250 mcg twice daily for 10 days, you need 5,000 mcg total—exactly one 5 mg vial. Reconstituting with 2 mL gives a concentration of 2,500 mcg/mL and a draw volume of 10 IU per dose, which is precise and easy to measure. The vial will be consumed in 10 days, well within the stability window.

Medium Protocols (4–8 Weeks)

For medium-duration protocols, consider both precision and stability. Multiple vials may be needed, so choose a reconstitution volume that produces consistent dose volumes across vials. Standardizing on a single reconstitution volume for a given peptide (e.g., always using 2 mL for 5 mg BPC-157 vials) eliminates the risk of accidentally using the wrong concentration when switching between vials.

Long Protocols (12+ Weeks)

For extended research protocols like a 16-week semaglutide titration, inventory planning becomes critical. Calculate the total peptide needed across the entire protocol, including dose escalation steps:

Example: 16-week semaglutide titration

Weeks	Dose/Week	Number of Weeks	Subtotal
1–4	250 mcg	4	1,000 mcg
5–8	500 mcg	4	2,000 mcg
9–12	1,000 mcg	4	4,000 mcg
13–16	1,700 mcg	4	6,800 mcg
Total			13,800 mcg (13.8 mg)

This 16-week protocol requires approximately three 5 mg vials of semaglutide. Given the weekly dosing schedule, each vial needs to remain stable for multiple weeks. Planning the reconstitution volume for each vial based on the doses it will deliver at that phase of the titration ensures optimal precision at each dose level.

Temperature and Stability Effects on Dosing Accuracy

Peptide stability directly affects dosing accuracy. A peptide that has partially degraded delivers less active compound per measured volume than the concentration calculation predicts. Understanding the factors that affect stability helps maintain dosing accuracy throughout a research protocol.

Degradation and Effective Concentration

When a reconstituted peptide degrades, the nominal concentration (calculated from the original vial amount and diluent volume) no longer reflects the actual concentration of active peptide. For example, if a vial was reconstituted at 2,500 mcg/mL but has degraded 15% over three weeks of improper storage, the effective concentration is only approximately 2,125 mcg/mL. Drawing what you believe is a 250 mcg dose (10 IU) actually delivers only about 213 mcg of active peptide.

To minimize this effect:

• Always store reconstituted peptides at 2–8°C (standard refrigerator temperature)
• Never freeze reconstituted peptide solutions, as freeze-thaw cycles can denature the peptide and create aggregates
• Protect from light by storing in the original vial (typically amber glass) or wrapping in aluminum foil
• Minimize the number of times you puncture the vial stopper, as each puncture introduces a potential contamination pathway despite the bacteriostatic water preservative
• Use reconstituted peptides within 4–6 weeks for most compounds; check our storage guide for compound-specific recommendations

Cold Chain Considerations During Shipping

Lyophilized (unreconstituted) peptides are significantly more stable than reconstituted solutions. Most lyophilized peptides can tolerate brief periods at room temperature during shipping without significant degradation. However, once reconstituted, the stability clock starts ticking. Plan your reconstitution timing so that you reconstitute vials only when you are ready to begin using them, not weeks in advance.

Calculating Doses from Blended Peptide Products

Some research peptides are supplied as pre-blended combinations containing multiple active compounds in a single vial. The Wolverine Blend (BPC-157 + TB-500) and Glow are examples. Calculating doses from blended products requires understanding the ratio and total amount of each component.

Wolverine Blend Example

The Wolverine Blend contains both BPC-157 and TB-500 in a single vial. When reconstituted, a single syringe draw delivers both peptides simultaneously. The calculation approach is the same as for single-peptide vials—you calculate based on one of the active ingredients (typically the one with the more precisely targeted dose) and accept that the other ingredient is delivered proportionally.

For researchers who need independent control over each peptide’s dose (for example, to titrate one while holding the other constant), purchasing separate vials of BPC-157 and TB-500 provides maximum flexibility. For researchers following a standard combined protocol, the blend offers the convenience of a single reconstitution and a single injection per administration. For background on why these two peptides are frequently combined, see our BPC-157 research guide and TB-500 research guide.

Record-Keeping and Documentation Best Practices

Accurate record-keeping is as important as accurate calculation. Without proper documentation, even perfectly calculated doses become unreliable over time as memory fades and vials accumulate.

Essential Information to Record

For every reconstituted vial, document the following on the vial label or in a research log:

• Peptide name and lot number (from the Certificate of Analysis)
• Vial amount (e.g., 5 mg)
• Date of reconstitution
• Volume of diluent added (e.g., 2.0 mL BAC water)
• Calculated concentration (e.g., 2,500 mcg/mL)
• Expiration date (typically 4–6 weeks post-reconstitution)

For each dose administered, record:

• Date and time of administration
• Volume drawn (in IU and mL)
• Calculated dose (in mcg)
• Injection site (to allow rotation)
• Any observations (solution clarity, injection site reactions, etc.)

This documentation serves multiple purposes: it ensures protocol adherence, enables accurate dose-response analysis, helps identify degradation issues (if results decline over a vial’s lifetime), and provides a reference when reordering supplies. For quality verification of your peptides, always review the Certificate of Analysis using our CoA interpretation guide.

Conclusion

Accurate peptide dosage calculation is a fundamental skill that underpins every successful research protocol. By mastering the unit conversions, concentration formulas, and syringe measurement techniques presented in this guide, researchers can ensure reproducible and reliable dosing across all peptide compounds. The key principles to remember are: always convert units before calculating, always verify your concentration after reconstitution, always use the smallest appropriate syringe for maximum precision, and always double-check your math before every administration.

For researchers just beginning their peptide work, we recommend starting with our complete reconstitution guide for the physical handling procedures, then returning to this dosage calculator guide for the mathematical framework. Together, these resources provide a complete foundation for precise and reproducible peptide research.

Browse our complete peptide catalog or explore our research hub for more in-depth articles on specific peptides, stacking strategies, and the latest breakthroughs in peptide science. For the latest developments in the field, see our overview of peptide research breakthroughs in 2025–2026.